Antidepressant Dopamine Norepinephrine Reuptake Inhibitors

Antidepressant dopamine and norepinephrine reuptake inhibitors constitute a distinct pharmacological class of second-generation psychotropic agents, predominantly exemplified in clinical practice by bupropion Rather than affecting serotonin, medications in this class exert their therapeutic effects by selectively inhibiting the presynaptic reuptake transporters for dopamine and norepinephrine, thereby enhancing neurotransmission of both monoamines within central neural pathways Clinically, these...

Antidepressant dopamine and norepinephrine reuptake inhibitors constitute a distinct pharmacological class of second-generation psychotropic agents, predominantly exemplified in clinical practice by bupropion

Rather than affecting serotonin, medications in this class exert their therapeutic effects by selectively inhibiting the presynaptic reuptake transporters for dopamine and norepinephrine, thereby enhancing neurotransmission of both monoamines within central neural pathways Clinically, these agents are primarily indicated for the treatment of major depressive disorder and seasonal affective disorder

Because of their activating properties and lack of direct serotonergic modulation, they are frequently utilized as alternative or add-on therapies when avoiding adverse effects such as sexual dysfunction, sedation, or weight gain is prioritized